-- （更正標題） 拜耳（BAYN.F）達成協議，將以最高24.5億美元的價格收購美國生物製藥公司Perfuse Therapeutics。 Perfuse Therapeutics專注於眼科疾病的治療。 根據週三發布的消息，根據擬議的交易條款，這家德國生命科學集團將向Perfuse Therapeutics支付3億美元的首付款，並根據里程碑事件支付後續款項。 拜耳將獲得PER-001的全部權益。 PER-001是一種正在研究的小分子內皮素受體拮抗劑，用於治療眼科疾病。該藥物目前正處於中期臨床開發階段，預計將成為治療青光眼和糖尿病視網膜病變的療法。 拜耳製藥業務發展與許可負責人尤爾根·埃克哈特表示：「透過此次收購，我們將增強我們在眼科領域的專業知識和產品線，並進一步鞏固我們致力於為患者開發急需療法的承諾。」他強調了這款在研藥物的潛力。 Perfuse Therapeutics 執行長兼創辦人塞夫吉·古爾坎也表達了類似的觀點，並指出該公司的願景與拜耳高度契合。 “他們擁有足夠的規模和全球資源，能夠充分發揮 PER-001 的潛力，從而改變人類失明的命運。” 此次收購預計將在獲得必要的監管機構和 Perfuse 股東批准後生效。 截至週三中午，拜耳股票在德國 Xetra 交易所的交易價格上漲超過 2%。
Related Articles
Mining & Metals
Copper Lake Resources to Launch 20-For-1 Reverse Stock Split
Copper Lake Resources (CPL.V) intends to consolidate its common shares on the basis of 20 pre-consolidation common shares for every one post-consolidation common share effective as of May 8, it said Wednesday.The company currently has 271-million common shares issued and outstanding, and following the consolidation, the company will have about 13.6-million common shares issued and outstanding, prior to rounding for fractional shares.Its outstanding options of 19.5-million and warrants of 15.9-million will also be adjusted on the same basis as the common shares with proportionate adjustments being made to exercise prices.Shares of the company were last seen unchanged at $0.02 on the TSX Venture Exchange.
$CPL.V
Sectors
US Total Crude Oil Stocks Fall in Week Ended May 1
US crude oil stocks, including those in the Strategic Petroleum Reserve, fell by 7.5 million barrels in the week ended May 1 following a decrease of 13.4 million barrels in the previous week.Excluding inventories in the SPR, commercial crude oil stocks decreased by 2.3 million barrels after a 6.2-million-barrel drop in the previous week, compared with the 3.4-million-barrel decrease expected in a survey compiled by Bloomberg as of 7:35 am ET.Stocks in the SPR declined by 5.2 million in the week after falling by 7.1 million in the previous week.Overall crude oil stocks were down 0.9% from the previous week but were still up 1.5% from a year earlier. Crude oil inventories are about 1% above the five-year average for this time of year.Gasoline stocks declined by 2.5 million barrels, compared with the 2.6-million-barrel decrease expected. Gasoline stocks edged lower by 1.1% from the previous week and 2.6% from a year earlier.Distillate stocks dropped by 1.3 million barrels in the current week, compared with an expected decrease of 2.3 million barrels. Distillate stocks were down 1.2% from the previous week and 4.1% lower than in the same week a year ago.Refineries operated at 90.1% of their capacity, up from 89.6% in the previous week.
Research
Research Alert: L: Q1 Revenue And Eps Miss, Though Results May Not Be Comparable To Consensus
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:L's Q1 revenue of CAD14.4B (+4% Y/Y) missed consensus by CAD90M, while adjusted EPS of CAD0.49 (+9% Y/Y) fell short of CAD0.52 estimates, though we think PC Financial's presentation in discontinued operations may affect comparability. Food retail same-store sales of 2.4% accelerated from Q4's 1.5%, with drug retail posting 4.1% growth. We view the solid same-store sales momentum as encouraging, particularly given internal food inflation remained well below the 4.4% CPI, indicating L's strong value proposition. Management reiterated 2026 guidance for high single-digit EPS growth and CAD2.4B in gross capex. Store expansion accelerated with 13 net openings, including five hard discount locations, aligning with consumer preference shifts toward value formats. Strong FCF of CAD621M (+189% Y/Y) supported aggressive share repurchases of CAD648M. We believe the pending PC Financial divestiture in Q3 2026 will simplify operations and provide additional capital flexibility for core retail growth.
$L